drugset / Trial / NCT00919633

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C

NCT00919633

Phase 2 Completed 116 enrolled Medtronic Corporate Technologies and New Ventures
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with chronic hepatitis C infection as compared to patients who receive standard treatment.

Timeline

Start
2009-06
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Peginterferon alfa-2b Protein / enzyme biologic 1.5 ug/kg Subcutaneous
Subject interferon alfa-2b Protein / enzyme biologic Subcutaneous
Background Ribavirin Small molecule Oral